Corcept Therapeutics CORT Ratios (2010-2026)

NASDAQ CORT
$75.03 +2.26 (+3.11%)
At close: Nov 9, 2026 · 4:00 PM EST
Reported Financials

Corcept Therapeutics Quarterly Ratios

Periods 66 quarters
Latest Sep 2026

Corcept Therapeutics reported a gross margin of 98.65% and a net margin of 36.56% for the quarter ended Sep 2026. These financial ratios cover 66 quarters of results from Jun 2010 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Profitability
Gross Margin
98.63%98.67%98.73%98.68%98.56%98.69%98.66%98.67%98.61%98.27%98.46%98.43%98.37%98.47%98.23%97.79%98.74%98.25%98.41%98.65%
EBT Margin
37.17%28.66%31.01%32.44%23.56%17.45%27.97%29.44%27.18%23.84%25.40%29.00%17.57%6.12%16.30%7.34%4.90%-27.12%17.93%35.34%
EBIT Margin
37.10%28.57%30.40%31.39%21.83%14.06%25.13%25.22%23.39%20.09%21.73%25.53%13.89%2.17%13.72%4.92%2.22%-30.08%16.12%33.70%
EBITDA Margin
37.39%28.88%30.51%31.58%22.47%14.33%25.49%25.41%23.55%20.21%21.78%25.70%14.04%2.47%13.96%4.89%2.36%-29.72%16.46%34.00%
Operating Margin
37.10%28.57%30.40%31.39%21.83%14.06%25.13%25.22%23.39%20.09%21.73%25.53%13.89%2.17%13.72%4.92%2.22%-30.08%16.12%33.70%
Net Margin
32.44%24.33%26.50%33.96%16.04%14.96%23.24%25.22%23.00%18.74%21.44%25.58%16.71%12.90%17.80%9.32%11.83%-18.92%16.45%36.56%
FCF Margin
49.95%37.61%17.43%32.73%32.37%24.57%35.84%42.78%4.08%16.18%24.89%39.25%32.95%2.97%22.75%26.24%19.00%-10.29%12.11%41.76%
Efficiency
Inventory AverageInventory Avg.
4.99M5.03M5.26M5.74M6.07M6.25M6.66M7.21M7.62M7.46M7.77M8.20M10.23M13.39M13.32M12.31M12.61M12.88M13.04M12.55M
Assets AverageAssets Avg.
504.58M445.94M482.24M514.81M558.34M600.64M571.24M559.32M607.77M638.73M685.25M749.41M812.41M843.50M824.09M812.66M830.13M825.77M851.79M961.36M
Equity AverageEquity Avg.
458.02M391.81M425.07M457.85M487.60M515.71M475.60M441.65M484.19M527.28M572.05M617.54M659.21M681.44M659.54M633.85M639.85M642.90M671.88M769.76M
Invested CapitalInvested Cap.
Asset Utilization RatioAsset Util.
0.730.850.810.770.720.690.750.800.790.820.830.840.830.810.870.910.920.930.981.00
Leverage & Solvency
Interest Coverage RatioInterest Cover
Debt Ratio
Times Interest Earned
Valuation
Price to EarningsP/E
18.6421.3922.6023.6321.6223.3324.2130.9131.8422.3827.1734.5237.9191.4258.6083.5437.5792.72173.4179.15
Price to SalesP/S
5.736.296.506.945.455.325.336.246.965.015.967.717.8517.6710.8011.804.845.6311.3113.09
Price to BookP/B
5.585.875.765.834.364.155.416.086.634.795.697.597.7917.7312.1613.835.696.7813.3215.13
Enterprise Value
1,874.08M2,047.24M2,176.87M2,363.88M1,758.46M1,735.12M1,918.40M2,453.74M2,990.37M2,211.82M2,921.80M4,468.66M4,913.31M11,789.66M7,392.06M8,320.51M3,315.46M3,989.16M9,090.96M12,240.43M
EV to EBIT
15.0615.5616.6118.6415.6117.2319.4025.0127.8718.1422.8431.1735.88106.3472.51126.8974.010.00M110.36
EV to EBITDA
14.9315.4316.7318.5115.4417.0119.1024.6127.5817.9922.7131.0035.66105.2671.43124.7272.160.00M108.19
Market Capitalization
2,097.61M2,392.77M2,546.96M2,760.14M2,190.13M2,200.18M2,281.66M2,808.97M3,358.59M2,622.58M3,394.96M4,848.99M5,296.64M12,112.43M7,734.29M8,742.19M3,687.62M4,327.34M9,399.16M12,611.13M
Price to FCFP/FCF
12.5313.4916.8520.3118.2619.8916.9318.2026.5421.0927.6234.2227.0168.4242.8553.5326.0136.0287.9164.80
EV to FCF
11.1911.5414.4017.3914.6615.6814.2315.9023.6317.7923.7731.5325.0566.6040.9550.9423.3833.2085.0362.89
EV to CFO
11.1611.5214.3817.3414.6115.6314.1815.8823.6117.7723.6831.0824.7865.7540.5250.8623.3533.1282.8761.79
Return Ratios
Return on Sales [ROS]ROS
37.10%28.57%30.40%31.39%21.83%14.06%25.13%25.22%23.39%20.09%21.73%25.53%13.89%2.17%13.72%4.92%2.22%-30.08%16.12%33.70%
Return on Capital Employed [ROCE]ROCE
27.24%33.86%30.26%27.46%23.18%19.30%20.68%22.43%21.32%22.52%21.89%23.00%20.39%15.83%15.01%10.24%6.75%-1.21%0.92%14.15%
Return on Invested Capital [ROIC]ROIC
Return on Assets [ROA]ROA
22.31%25.07%23.36%22.68%18.15%15.72%16.56%16.33%17.46%18.48%18.39%18.93%17.39%15.89%16.23%13.07%12.01%5.74%6.48%16.89%
Return on Equity [ROE]ROE
24.58%28.53%26.50%25.50%20.78%18.31%19.89%20.68%21.92%22.39%22.03%22.97%21.43%19.67%20.28%16.75%15.58%7.38%8.22%21.09%

Corcept Therapeutics Ratios API

Pull Corcept Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CORT&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY